International Stroke Trial "IST"


Phase 3 Results

Trial Description

To assess the safety and efficacy of antithrombotic therapy.


Trial Design

Randomized, open trial involving 19435 patients.

Patient Involvement

Half of the 19,435 participating patients received unfractionated heparin (5000 or 12,500 IU twice daily) and half were told to avoid heparin. In a factorial design, half received aspirin 300 mg daily and half were told to avoid aspirin. Treatment was continued for 14 days or until hospital discharge.


Type Measure Time Frame Safety Issue
Primary Death within 14 days and death or dependency at 6 months.